AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL
· Real-Time Price · USD
5.84
-0.26 (-4.26%)
At close: Oct 16, 2025, 3:59 PM
5.72
-2.05%
After-hours: Oct 16, 2025, 07:59 PM EDT
-4.26% (1D)
| Bid | 5.84 |
| Market Cap | 1.75B |
| Revenue (ttm) | 32.88M |
| Net Income (ttm) | -165.66M |
| EPS (ttm) | -0.56 |
| PE Ratio (ttm) | -10.43 |
| Forward PE | -12.22 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 6.04 |
| Volume | 5,401,483 |
| Avg. Volume (20D) | 5,696,187 |
| Open | 6.11 |
| Previous Close | 6.10 |
| Day's Range | 5.77 - 6.22 |
| 52-Week Range | 1.89 - 6.51 |
| Beta | 0.69 |
| Ex-Dividend Date | n/a |
About ABCL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ABCL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ABCL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAbCellera Biologics Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+0.24%
ABCL stock has given up its prior gain. AbCellera ...
Unlock content with
Pro Subscription
2 months ago
+0.24%
AbCellera Biologics shares are trading higher after the company reported better-than-expected Q2 financial results and announced the dosing initiation of its Phase 1 ABCL635 trial.
2 months ago · seekingalpha.com
AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call TranscriptAbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Andrew Booth - Chief Financial Officer Carl L.G. Hansen - CEO, President & Chair...
